Rheumatology International

, Volume 14, Issue 5, pp 207–211 | Cite as

Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus

Relationhip with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy
  • A. Doria
  • A. Ghirardello
  • M. Boscaro
  • M. L. Viero
  • E. Vaccaro
  • G. M. Patrassi
  • P. F. Gambari
Original Article


Endothelial cell damage in systemic lupus erythematosus (SLE) was evaluated by measuring fibrinolytic activity and von Willebrand factor levels. Tissuetype plasminogen activator (t-PA) antigen, plasminogen activator inhibitor (PAI) activity, and von Willebrand factor antigen (vWF:Ag) and activity (vWF:RCof) were measured in 21 SLE patients (12 of whom were therapy free) and 22 controls. In addition, the relationship between such parameters and Raynaud's phenomenon, disease activity [according to personal criteria, Systemic Lupus Activity Measure (SLAM) and European Consensus Lupus Activity Measurement (ECLAM) scores], inflammatory indices [ESR, C-reactive protein (CRP), α2-globulin], anticardiolipin antibodies and corticosteroid therapy was investigated. Lower levels of t-PA antigen (P=0.003) and higher levels of vWF:Ag (P=0.001) were found in SLE patients in comparison with controls. Moreover, t-PA antigen was lower (P=0.02) in steroidfree patients in comparison with those taking steroids. No relationship was found between fibrinolysis and coagulation abnormalities and Raynaud's phenomenon, disease activity, inflammatory indices and anticardiolipin antibodies. Endothelial cell damage is probably a common feature in SLE patients; nervertheless, we were unable to clarify the nature of such abnormality. It is worth noting that low doses of steroids seem to be effective in improving endothelial cell function in SLE patients.

Key words

Fibrinolysis Systemic lupus erythematosus Tissue plasminogen activator Endothelial injury Antiphospholipid antibodies Corticosteroid therapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kahaleh MB (1990) The role of vascular endothelium in the pathogenesis of connective tissue disease: endothelial injury, activation, participation and response. Clin Exp Rheumatol 8:595–601Google Scholar
  2. 2.
    Byron MA, Allington MJ, Chapel HM, Mowat AG, Cederholm-Williams SA (1987) Indications of vascular endothelial cell dysfunction in systemic lupus erythematosus. Ann Rheum Dis 46:741–745Google Scholar
  3. 3.
    Angles-Cano E, Sultan Y, Clauvel JP (1979) Predisposing factors to thrombosis in systemic lupus erythematosus. Possible relation to endothelial cell damage. J Lab Clin Med 94:312–323Google Scholar
  4. 4.
    Belch JJF, Zoma A, McLaughlin K, Curran L, Capell HA, Forbes CD, Sturrock RD (1987) Fibrinolysis in systemic lupus erythematosus: effect of desamino D-arginine vasopressin infusion. Br J Rheumatol 26:262–266Google Scholar
  5. 5.
    Jordan JM, Allen NB, Pizzo SV (1987) Defective release of tissue plasminogen activator in systemic and cutaneous vasculitis. Am J Med 82:397–400Google Scholar
  6. 6.
    Violi F, Ferro D, Valesini G, Quintarelli C, Saliola M, Grandilli MA, Balsano F (1990) Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis. BMJ 300:1099–1102Google Scholar
  7. 7.
    Woolf D, Wakerley G, Wallington TB, Scott DGI, Dieppe PA (1987) Factor VIII related antigen in the assessment of vasculitis. Ann Rheum Dis 46:441–447Google Scholar
  8. 8.
    Love PE, Santoro SA (1990) Ahtiphospholipid antibodies: anticardiolipin and lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 112:682–698Google Scholar
  9. 9.
    Brey RL, Coull BM (1992) Antiphospholipid antibodies: origin, specificity, and mechanism of action. Stroke [Suppl I] 23:15–18Google Scholar
  10. 10.
    Ghirardello A, Doria A, Ruffatti A, Rigoli AM, Vesco P, Calligaro A, Gambari PF (1994) Antiphospholipid antibodies (aPL) in systemic lupus erythematosus (SLE). Are they specific tools for the diagnosis of aPL syndrome in SLE? Ann Rheum Dis 53:140–142Google Scholar
  11. 11.
    Tan EM, Cohen AS, Fries JF (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277Google Scholar
  12. 12.
    Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, Bombardieri S and the European Consensus Study Group for Disease Activity in SLE (1992) Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. Clin Exp Rheumatol 10:549–554Google Scholar
  13. 13.
    Liang MH, Socher SA, Larson MG, Schur PH (1989) Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32:1107–1118Google Scholar
  14. 14.
    Laurell CB (1966) Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 15:45–52Google Scholar
  15. 15.
    Casonato A, Fabris F, Vicariotto M, Girolami A (1985) The evaluation of factor VIII antigen by means of a simple slide test. Am J Clin Pathol 84:107–111Google Scholar
  16. 16.
    Thiagarajan P, Pengo V, Shapiro SS (1986) The use of the diluted Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 4:869–874Google Scholar
  17. 17.
    Gharavi AE, Harris EN, Asherson RA, Hughes GRV (1987) Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 46:1–6Google Scholar
  18. 18.
    Bunn CC, Gharavi AE, Hughes GRV (1982) Antibodies to extractable nuclear antigens in 173 patients with DNA-binding positive SLE: an association between antibodies to ribonucleoprotein and Sm antigens observed be counterimmuno-electrophoresis. J Clin Lab Immunol 8:13–17Google Scholar
  19. 19.
    Jaffe EA, Hoyer LW, Nachmann RL (1974) Synthesis of von Willebrand factor by cultured human endothelial cell. Proc Natl Acad Sci USA 71:1906–1911Google Scholar
  20. 20.
    Van Mourik JA, Lawrence DA, Loskutof DJ (1984) Purification of an inhibitor of plasminogen activator (anti-activator) synthesized by endothelial cells. J Biol Chem 259:14914–14921Google Scholar
  21. 21.
    Astedt B, Pandolfi M (1972) On release and synthesis of fibrinolytic activators in human organ culture. Eur J Clin Biol Res 17:261–267Google Scholar
  22. 22.
    Patrassi GM, Sartori MT, Casonato A, Viero ML, Pontara E, Saggiorato G, Girolami A (1992) Urokinase-type plasminogen activator release after DDAVP in von Willebrand disease: different behaviour of plasminogen activator according to the synthesis of von Willebrand factor. Thromb Res 66:517–526Google Scholar
  23. 23.
    Awada H, Barlowatz-Meimon G, Dourgados M, Maisonneuve P, Sultan Y, Amor B (1988) Fibrinolysis abnormalities in systemic lupus erythematosus and their relation to vasculitis. J Lab Clin Med 111:229–236Google Scholar
  24. 24.
    Nilsson TK, Löfvenberg E (1989) Decreased fibrinolytic capacity and increased von Willebrand factor levels as indicators of endothelial cell dysfunction in patients with lupus anticoagulant. Clin Rheumatol 8:58–63Google Scholar
  25. 25.
    Editorial (1993) Von Willebrand factor as a marker of injury to the endothelium in inflammatory vascular disease. J Rheumatol 20:1469–1471Google Scholar
  26. 26.
    Francis RB Jr (1989) Clinical disorders of fibrinolysis: a critical review. Blut 59:1–14Google Scholar
  27. 27.
    Blann AD, Illingworth K, Jayson MIV (1993) Mechanism of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol 20:1325–1330Google Scholar
  28. 28.
    Jurado M, Paramo JA, Gutierrez-Pimentel M, Rocha E (1992) Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders. Thromb Haemost 68:516–520Google Scholar
  29. 29.
    Ruiz-Argüelles GJ, Ruiz-Argüelles A, Lobato-Mednizábal E, Diaz-Gomez F, Pacheco-Pantoja E, Drenkard C, Alarcon-Segovia D (1991) Disturbances in the tissue plasminogen activator/plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematosus. Am J Haematol 37:9–13Google Scholar
  30. 30.
    Wiman B, Hamsten A (1990) The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost 16:207–216Google Scholar
  31. 31.
    Guariso G, Ruffatti A, Casonato A, Drigo P, Ghirardello A, Zancan L (1992) Antiphospholipid syndrome in a child with trisomy 21: the relationship between anticardiolipin G antibodies and the von Willebrand factor. Clin Exp Rheumatol 10:613–616Google Scholar
  32. 32.
    Rose PE, Struthers GS, Robertson M, Kavi J, Chant I, Taylor CM (1990) Factor VIII von Willebrand protein in haemolytic uraemic syndrome and systemic vasculitides. Lancet I: 500–502Google Scholar
  33. 33.
    Blann AD (1991) Von Willebrand factor antigen as an acute phase reactant and marker of endothelial cell injury in connective tissue disease: a comparison with CRP, rheumatoid factor, and erythrocyte sedimentation rate. Z Rheumatol 50:320–322Google Scholar
  34. 34.
    Isacson S (1970) Effect of prednisone on the coagulation and fibrinolytic systems. Scand J Haematol 7:212–216Google Scholar
  35. 35.
    Patrassi GM, Sartori MT, Viero ML, Scarano L, Boscaro M, Girolami A (1992) The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coag Fibrinol 3:789–793Google Scholar
  36. 36.
    Derksen RHWM, Hasselaar P, Oosting JD, De Groot PhG (1990) The antiphospholipid antibody dilemma. Clin Rheum 9 (S):39–44Google Scholar
  37. 37.
    Kordich LC, Forastiero RR, Basilotta E, Porterie P, Carreras LO (1992) Natural inhibitors of blood coagulation and fibrinolysis in patients with lupus anticoagulant. Blood Coagul Fibrinolysis 3:765–771Google Scholar
  38. 38.
    Matsuda J, Kawasugi K, Gohchi K, Saitoh N, Tsukamoto M, Kazama M, Kinoshita T (1992) Clinical significance of the venous occlusion test on systemic lupus erythematosus patients with a focus on changes in blood levels of tissue plaminogen activator, von Willebrand factor antigen, and thrombomodulin. Acta Haematol 88:22–26Google Scholar
  39. 39.
    Keeling DM, Campbell SJ, Mackie IJ, Machin SJ, Isenberg DA (1991) The fibrinolytic response to venous occlusion and the natural anticoagulants in patients with antiphospholipoid antibodies both with and without systemic lupus erythematosus. Br J Haematol 77:354–359Google Scholar
  40. 40.
    Francis RB, McGehee WG, Feinstein DI (1988) Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis. Thromb Haemost 59:412–414Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • A. Doria
    • 1
  • A. Ghirardello
    • 1
  • M. Boscaro
    • 2
  • M. L. Viero
    • 2
  • E. Vaccaro
    • 1
  • G. M. Patrassi
    • 2
  • P. F. Gambari
    • 1
  1. 1.Division of Rheumatology, Institute of Internal MedicineUniversity of PadovaPadovaItaly
  2. 2.IV Chair of Internal MedicineUniversity of PadovaPadovaItaly

Personalised recommendations